UNSPSC 51111785: Pertuzumab

Pertuzumab is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

UNSPSC 51111785 Pertuzumab is a Commodity code representing a specific pharmaceutical product—a trastuzumab deruzumab (HER2-targeted monoclonal antibody) used in oncology treatment. State and local governments procure pertuzumab primarily through cooperative purchasing vehicles and multi-jurisdictional pharmaceutical agreements rather than direct institutional buys, with the product supplied via authorized pharmaceutical wholesalers to health departments, county health systems, and public hospital networks. The recent opportunities block contains no solicitations specifically requesting pertuzumab, one notice of an administrative office relocation unrelated to procurement, one closed pharmaceutical opportunity (Seminole County naloxone procurement due July 2023, now well past deadline), one multi-state generic pharmaceutical cooperative (MMCAP) that covers OTC and generic medications but does not name pertuzumab, and multiple vendor networking events and forums rather than formal solicitations. The code shows no active, relevant state or local procurement activity in the recent-opportunities dataset.

No recent pertuzumab-specific solicitations are present in the source material. The MMCAP cooperative purchasing vehicle listed covers generic multi-source pharmaceuticals and over-the-counter products for state and local use across Minnesota, Oregon, and other participating jurisdictions, but pertuzumab—a branded specialty pharmaceutical requiring oncology protocols and restricted distribution—falls outside that scope. The absence of recent opportunities under this code signals either narrow demand (limited to specialized cancer centers and large public hospital systems with oncology programs) or routing through existing national specialty pharmaceutical contracts and GPOs rather than state and local competitive solicitations.